PM
KZR

Prosight Management’s Kezar Life Sciences KZR Stock Holding History

Prosight Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,000
Closed -$626K – 45
2023
Q1 		$626K Buy
+20,000
New +$1.16M 0.3% 33

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Prosight Management's KZR Position: Q3 2024 in Review

Prosight Management sold out of Kezar Life Sciences (KZR) in Q3 2024, closing a stake of 5,608 shares — an estimated $33.6K sold.

Prosight Management first reported a position in KZR in Q2 2018 and held it in 20 quarters. The position peaked at $12.4M in Q4 2022. 59 funds tracked by Wall St. Rank hold KZR as of Q3 2024.

  • Prosight Management reported no remaining Kezar Life Sciences position as of Q3 2024 after selling out during the quarter.
  • Prosight Management sold 5,608 Kezar Life Sciences shares in Q3 2024, an estimated $33.6K.
  • Prosight Management first reported a position in Kezar Life Sciences in Q2 2018 and held it in 20 quarters.
  • Prosight Management's Kezar Life Sciences position peaked at $12.4M in Q4 2022.
  • 59 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2024.

Based on Prosight Management's 13F filing for Q3 2024, filed 14 Nov 2024.